{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:06:34Z","timestamp":1768316794784,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"DOI":"10.1007\/s10689-025-00478-4","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T09:31:39Z","timestamp":1749720699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hereditary breast cancer beyond BRCA: clinicopathological characteristics and long-term outcomes"],"prefix":"10.1007","volume":"24","author":[{"given":"Kwinten","family":"Dejaegher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Nevelsteen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sileny","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Punie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"issue":"6","key":"478_CR1","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1245\/s10434-020-09158-2","volume":"28","author":"C Bergstrom","year":"2021","unstructured":"Bergstrom C, Pence C, Berg J, Partain N, Sadeghi N et al (2021) Clinicopathological features and outcomes in individuals with breast cancer and ATM, CHEK2, or PALB2 mutations. Ann Surg Oncol 28(6):3383\u20133393","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"478_CR2","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","volume":"28","author":"R Yoshida","year":"2021","unstructured":"Yoshida R (2021) Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer 28(6):1167\u20131180","journal-title":"Breast Cancer"},{"key":"478_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4137\/BCBCR.S18715","volume":"8","author":"MJ Larsen","year":"2014","unstructured":"Larsen MJ, Thomassen M, Gerdes AM, Kruse TA (2014) Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl) 8:145\u2013155","journal-title":"Breast Cancer (Auckl)"},{"issue":"suppl 5","key":"478_CR4","doi-asserted-by":"publisher","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","volume":"27","author":"S Paluch-Shimon","year":"2016","unstructured":"Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ et al (2016) Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol 27(suppl 5):v103\u2013v110","journal-title":"Ann Oncol"},{"key":"478_CR5","first-page":"6384190","volume":"2020","author":"Piombino C, Cortesi L, Lambertini M","year":"2020","unstructured":"Piombino C, Cortesi L, Lambertini M, Punie K, Grandi G, Toss A (2020) Secondary prevention in hereditary breast and\/or ovarian cancer syndromes other than BRCA. J Oncol 2020:6384190","journal-title":"J Oncol"},{"issue":"5","key":"478_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"CAC Breast","year":"2021","unstructured":"Breast CAC, Dorling L, Carvalho S, Allen J, Gonz\u00e1lez-Neira A, Luccarini C et al (2021) Breast cancer risk genes\u2014association analysis in more than 113,000 women. N Engl J Med 384(5):428\u2013439","journal-title":"N Engl J Med"},{"key":"478_CR7","unstructured":"BRCA Gene Mutations: Cancer Risk and Genetic Testing Fact Sheet (2020, 19 November) National Cancer Institute. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet"},{"issue":"18","key":"478_CR8","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.20.00299","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I et al (2020) Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline. J Clin Oncol 38(18):2080\u20132106","journal-title":"J Clin Oncol"},{"issue":"3","key":"478_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","volume":"133","author":"S Masciari","year":"2012","unstructured":"Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN et al (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133(3):1125\u201330","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"478_CR10","first-page":"6643","volume":"63","author":"M Olivier","year":"2003","unstructured":"Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P et al (2003) Li-Fraumeni and related syndromes: correlation between tumour type, family structure, and TP53 genotype. Cancer Res 63(20):6643\u201350","journal-title":"Cancer Res"},{"issue":"10","key":"478_CR11","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG (2020) European Reference Network GENTURIS Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet 28(10):1379\u20131386","journal-title":"Eur J Hum Genet"},{"issue":"14","key":"478_CR12","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1002\/cncr.32905","volume":"126","author":"J Zhou","year":"2020","unstructured":"Zhou J, Wang H, Fu F, Li Z, Feng Q et al (2020) Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing. Cancer 126(14):3202\u20133208","journal-title":"Cancer"},{"issue":"17","key":"478_CR13","first-page":"1651","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Foulkes WD, Tischkowitz M (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371(17):1651\u20132","journal-title":"N Engl J Med"},{"issue":"9","key":"478_CR14","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-08-3128","volume":"15","author":"T Heikkinen","year":"2009","unstructured":"Heikkinen T, K\u00e4rkk\u00e4inen H, Aaltonen K, Milne RL, Heikkil\u00e4 P et al (2009) The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumour phenotype. Clin Cancer Res 15(9):3214\u201322","journal-title":"Clin Cancer Res"},{"issue":"1","key":"478_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13058-016-0758-5","volume":"18","author":"TA Muranen","year":"2016","unstructured":"Muranen TA, Blomqvist C, D\u00f6rk T, Jakubowska A, Heikkil\u00e4 P et al (2016) Patient survival and tumour characteristics associated with CHEK2:p.I157T\u2014findings from the breast cancer association consortium. Breast Cancer Res 18(1):98","journal-title":"Breast Cancer Res"},{"issue":"1","key":"478_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13058-018-0951-9","volume":"20","author":"AL Renault","year":"2018","unstructured":"Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E et al (2018) Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Res 20(1):28","journal-title":"Breast Cancer Res"},{"issue":"16","key":"478_CR17","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1056\/NEJMp058197","volume":"353","author":"Burstein HJ","year":"2005","unstructured":"Burstein HJ (2005) The distinctive nature of HER2-positive breast cancers. N Engl J Med 353(16):1652\u20134","journal-title":"N Engl J Med"},{"issue":"20","key":"478_CR18","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938\u201348","journal-title":"N Engl J Med"},{"key":"478_CR19","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology genetic\/familial high-risk assessment: breast, ovarian, pancreatic and prostate. Version 2.2025. National Comprehensive Cancer Network; November 7, 2024"},{"key":"478_CR20","first-page":"e225162","volume":"9","author":"Reid S, Roberson ML, Koehler K, Sha","year":"2022","unstructured":"Reid S, Roberson ML, Koehler K, Shah T, Weidner A, Whisenant JG, Pal T (2022) Receipt of bilateral mastectomy among women with hereditary breast cancer. JAMA Oncol 9:e225162","journal-title":"JAMA Oncol"},{"key":"478_CR21","first-page":"227","volume":"13","author":"PS Peleg Hasson","year":"2020","unstructured":"Peleg Hasson PS, Menes T, Sonnenblick A (2020) Comparison of patient susceptibility genes across breast cancer: implications for prognosis and therapeutic outcomes. Pharmgenomics Pers Med 13:227\u2013238","journal-title":"Pharmgenomics Pers Med"},{"key":"478_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1748-717X-5-104","volume":"5","author":"S Heymann","year":"2010","unstructured":"Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T et al (2010) Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5:104","journal-title":"Radiat Oncol"},{"issue":"1","key":"478_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2014.10.008","volume":"41","author":"P Economopoulou","year":"2015","unstructured":"Economopoulou P, Dimitriadis G, Psyrri A (2015) Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat Rev 41(1):1\u20138","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"478_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/pai.13020","volume":"30","author":"P Amirifar","year":"2019","unstructured":"Amirifar P, Ranjouri MR, Yazdani R, Abolhassani H, Aghamohammadi A (2019) Ataxia-telangiectasia: a review of clinical features and molecular pathology. Pediatr Allergy Immunol 30(3):277\u2013288","journal-title":"Pediatr Allergy Immunol"},{"issue":"7","key":"478_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jnci\/djq055","volume":"102","author":"JL Bernstein","year":"2010","unstructured":"Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE et al (2010) WECARE Study Collaborative Group. Radiation exposure, the ATM gene, and contralateral breast cancer in the women\u2019s environmental cancer and radiation epidemiology study. J Natl Cancer Inst 102(7):475\u201383","journal-title":"J Natl Cancer Inst"},{"key":"478_CR26","doi-asserted-by":"crossref","unstructured":"Modlin LA, Flynn J, Zhang Z, Cahlon O, Mueller B et al (2021) Tolerability of breast radiotherapy among carriers of ATM germline variants. JCO Precis Oncol 5:PO.20.00334","DOI":"10.1200\/PO.20.00334"},{"issue":"18","key":"478_CR27","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1001\/jama.286.18.2233","volume":"286","author":"Su Y, Swift M.","year":"2001","unstructured":"Su Y, Swift M. (2001) Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations. JAMA 286(18):2233\u20134","journal-title":"JAMA"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00478-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-025-00478-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00478-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:57:56Z","timestamp":1750913876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-025-00478-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["478"],"URL":"https:\/\/doi.org\/10.1007\/s10689-025-00478-4","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare having no conflict of interest in the realisation of this research article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"54"}}